

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: 10-4-2008

To,

The Manager,  
Printing Corporation of Pakistan Press,  
University Road,  
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 01-3-2008 TO BE PUBLISHED ON 11-4-2008 IN  
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

193/2008	<b><u>26-2-2008</u></b> World Wide Stationery Manufacturing Company Limited. Hong Kong (Priority 21-11-07 Europe)	“A lever-arch type file mechanism”
194/2008	E-Manual System SDN. BHD Malaysia (Priority 02-3-07 Malaysia)	“A method of data storage and management”
195/2008	Shell Internationale Research Maatschappij B.V. The Netherlands (Priority 28-2-07 Japan)	“Fuel composition for diesel engines”
196/2008	Laboratorios Almirall, S.A. Spain (Priority 02-3-07 Spain)	“New process for preparing 3-methyl-4- phenylisoxazolo [3,4-D[pyridazin-7(6H)- one”
197/2008	Eisai R&D Management Co, Ltd. Japan (Priority 28-2-07 Japan)	“Two cyclic oxomorphorin derivatives”
198/2008	<b><u>27-2-2008</u></b> Occupational & Medical Innovations Ltd. Australia (Priority 02-3-07 Australia)	“A syringe with rear plunger lock”
199/2008	AstraZeneca AB, Sweden (Priority 06-3-07 US)	“Novel 2-heteroaryl substituted benzophenes and benzofuranes 709”
200/2008	Glaxo Group Limited, United Kingdom (Priority 01-3-07 USA)	“Novel dosage form”
201/2008	1.Glaxo Group Limited, United Kingdom 2.NeuroSearch A/S	“Novel salt”

	Denmark (Priority 01-3-07 GB)	
202/2008	AiCuris GmbH & Co., KG Germany (Priority 5-11-04 Germany)	“A salt, solvate and solvate of the salt of a lysobactin derivative with improved antibacterial effect and better tolerability”
203/2008	Glaxo Group Limited, United Kingdom (Priority 01-3-07 US)	“Novel dosage form”
204/2008	BASF SE Germany (Priority 01-3-07 US)	“Pesticidal mixtures comprising aminothiazoline compounds”
205/2008	Takeda Pharmaceutical Company Limited, Japan (Priority 28-2-07 Japan)	“Pyrrole compounds”
206/2008	Schering Corporation, USA (Priority 02-3-07 USA)	“Benzimidazole derivatives and methods of use thereof”
207/2008	Schering Corporation, USA (Priority 02-3-07 USA)	“Piperidine derivatives and methods of use thereof”
	<b><u>28-2-2008</u></b>	
208/2008	Reckitt Benckiser HealthCare (UK) Limited. United Kingdom (Priority 01-3-07 British)	“Improvements in or relating to medicinal compositions”
209/2008	Reckitt Benckiser HealthCare (UK) Limited. United Kingdom (Priority 01-3-07 British)	“Improvements in or relating to medicinal compositions”
210/2008	Reckitt Benckiser HealthCare (UK) Limited. United Kingdom (Priority 01-3-07 British)	“Improvements in or relating to medicinal compositions”
211/2008	Reckitt Benckiser HealthCare (UK) Limited. United Kingdom (Priority 01-3-07 British)	“Improvements in or relating to medicinal compositions”

212/2008	1. Novartis AG, Switzerland 2. Vernalis (R&D) Ltd. Great Britain (Priority 01-3-07 Europe)	“Acid addition salts, hydrates and polymorphs 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms”
213/2008	Novartis AG, Switzerland (Priority 02-3-07 Europe)	“Pharmaceutical compositions”
214/2008	Omya Development AG, Switzerland (Priority 21-3-07 Europe)	“Surface-reacted calcium carbonate and its use in waste water treatment”
215/2008	SAAB AB, Sweden (Priority 28-2-07 EP)	“Device for testing cables”
216/2008	Novartis AG, Switzerland (Priority 02-3-07 US)	“Solid forms of a raf kinase inhibitor”
217/2008	Haldor Topsoe A/S, Denmark	“Process and catalyst for hydrogenation of carbon oxides”
218/2008	Satake Corporation, Japan (Priority 09-3-07 Japan)	“Method of producing parboiled rice and parboiled rice produced by the method”
219/2008	<b><u>29-2-2008</u></b> Mr. Noor Muhammad Hyderabad(Sindh) Pakistan.	“New double spark plug fitting technology /efficient carburetion system”
220/2008	Abdul Raheem Shaikh Hyderabad Sindh, Pakistan	“Improved chasis/ frame for motor bike to accommodate gas cylinder containing fuel gas”
221/2008	GlaxoSmithKline Biologicals s.a. Belgium (Priority 2-3-07 USA)	“Novel method and compositions”
222/2008	Laboratorios Almirall, S.A Spain	“New 3-([1,2,4]triazolo[4,3-A]pyridine-7-yl)benzamide derivatives”

(Priority 2-3-07 Spain)

223/2008	<b><u>01-3-2008</u></b> Honda Motor Co., Ltd. Japan (Priority 30-5-07 Japan)	“LEG Shield structure of motorcycle”
224/2008	Tahera Khatoon PCSIR Labs, Karachi, Pakistan	“A process for the formulation of zinc- manganese ethylene-bis-dithiocarbamate (an agricultural fungicide)”

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


344/1997      Bayer  
                 aktiengesellschaft.  
                 Germany.

“herbicidal composition based on heteroaryloxy  
acetamide”

(INT: CL, AOIN 25/32)

139439

Heteroaryloxy-acetamide of the general formula (I)



in which

Het represents thiadiazolyl which is substituted by halogen or by C1-C4-alkyl or phenyl, each of which is optionally substituted by halogen, and. Ar represents optionally halogen-, C1-C4-alkyl- or C1-C4-halogenoalkyl-substituted phenyl. can be used with good results as selective herbicides in rice cultivation. The novel herbicidal active compound combinations comprising (1) a heteroaryloxy-acetamide of the formula (I) above and (2) in each case one active compound from the group of already known selective rice herbicides exhibit, at certain weight ratios, synergistic activities and can be used particularly advantageously as selective herbicides in


398/1997 Janssen  
Pharmaceutica N.V.  
Belgium.

rice crops.  
"Alkylaminobenzothiazole compound"

(INT: CL, CO7D 277/82, A61K 31/42)

139440

The present invention concerns the compound of formula



the N-oxide forms, wherein X is O or S; n is 2, 3, 4 or 5; R1 is hydrogen, C1-6alkyl, C1-6alkyloxy or halo; R2 is hydrogen, C1-6alkyl, phenyl, phenyl C1-6alkyl or phenylcarbonyl; R3 and R4 each independently are selected from hydrogen, halo, nitro, C1-6alkyl, C1-6alkyloxy, haloC1-6alkyl, aminosulfonyl, mono- or di C1-4alkyl)aminosulfonyl; or (R)3 and (R)4 may also be taken together to form a bivalent radical of formula -CH=CH-CH=CH-; compound of formula (I) containing a radioactive isotope;


399/1997 Janssen  
Pharmaceutica N.V.  
Belgium.

"2,4-Diaminopyrimidine compound"

(INT: CL, C07D 401/12, A61K 31/505)

139441

The present invention concerns the compound of formula




the N-oxide forms, wherein Alk is C1-6alkanediyl or C3-6alkanediyl; R1 is hydrogen or C1-4alkyl; R2 and R3 each independently are hydrogen, C1-6alkyl or C3-7cycloalkyl; or R2 and R3 may also be taken together with the nitrogen atom to which they are attached, thus forming a pyrrolidine, a piperidine or a perhydro azepine ring; R4 is hydrogen or halo; Q is aryl, aryloxy, di(aryl)methyl or heteroaryl; aryl is




atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminomethyl, N-alkylaminomethyl of 2-7 carbon atoms, N,N-dialkylaminomethyl of 3-7 carbon atoms, mercapto, methylmercapto, and benzylamino;

R<sub>2</sub> is selected from the group consisting of



R<sub>5</sub> is independently and exclusively hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms; R<sub>1</sub> is hydrogen, halogen, alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms; R<sub>4</sub> is hydrogen, halogen, alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms; and R<sub>3</sub> is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, or trifluoromethyl; X is not a phenyl ring exclusively substituted with one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl; cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, amino, and alkanoylamino of 1-6 carbon atoms; Further provided that when R<sub>2</sub> is



and R<sub>5</sub> is hydrogen or alkyl of 1-6 carbon atoms, R<sub>3</sub> is not halogen; and still further provided that When R<sub>6</sub> is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom; and finally provided that

When Y is -NR6-or R7 is -NR6R6 then g=2-6;  
When M is -O- and R7 is -OR6 then p=1-4; When  
Y is -NR6-then k=2-4; When Y is -)-and M or W is  
-O-then k=1-4 and when W is a bond with het  
bonded through a nitrogen atom and Y is -O-or -  
NR6-then k=2-4; Which are useful as antineoplastic  
agents and in the treatment of certain kidney  
diseases, such as polycystic kidney disease.

824/1998 Bayer  
Aktiengesellschaft  
Germany.

“Composition containing O-ethyl O-(8-  
quinolyl)phenyl thiophosphate (quintiofos)”

(A0IN 57/30)

139443

The present invention relates to long-acting  
composition against wood-destroying insects,  
characterized in that they contain a) insecticidally  
active compound b) organic natural compound or  
organic synthetic compounds or mixture thereof  
as carrier material, c) optionally microbicidally  
active compounds, d) optionally attractants or  
development-inhibitory compound for insects, e) and  
optionally formulation auxiliaries.


376/2000 Pfizer Products Inc.  
USA.

“1-Benzyl-6-methoxy-3,4-dihydro-1H-naphthalen-2-  
one”

(A61K, 13/00)

139444

The present invention provides non-steroidal  
compound of formula I which are selective  
modulators (i.e., agonists and antagonists) of a  
steroid receptor, specifically, the glucocorticoid  
receptor. The present invention also provides  
pharmaceutical compositions containing these  
compounds and methods for using these compound  
to treat animals requiring glucocorticoid receptor  
agonist or antagonist therapy. Glucocorticoid  
receptor modulators are useful to treat diseases, such  
as obesity, diabetes, inflammation and others as  
described below.




891/2000 Pfizer Inc.  
USA.

“Polymorphic form of 3-(N-methyl-2(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1H-indole hemisulphate”

(INT: CL, C07D 403/06)

139445

The present invention is concerned with a crystalline, polymorphic form of a compound of formula (I)



characterised by a powder X-ray diffraction pattern obtained using copper K-alpha radiation ( $A = 0.15046\text{nm}$ ) which shows main peaks at 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98, 19.48, 20.70, 21.29, 21.45, 22.21, 22.64, 23.08, 25.20 and 25.79.

The invention also relates for use in the treatment of conditions for which an agonist of 5-HT<sub>1</sub> receptors is indicated, for example, migraine.


1133/2000 Pfizer Products Inc.  
USA.

“Pyrrolo[2,3-d]pyrimidine compound”

(INT: CL, C07D 487/04)

139446

A compound of the formula



wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.







1023/2003 Wyeth  
USA.

“Thieno (3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles ”

(C07D 519/00)

139447

This invention provides compound of Formula (1a)-(1f)



wherein:

X, R1, and R2 are defined hereinbefore in the specification, which are useful in the treatment of cancer, stroke, osteoporosis, polycystic kidney disease, autoimmune disease, rheumatoid arthritis, and transplant rejection.


791/2006 Wyeth Holdings  
Corporation.  
USA.

“Pharmaceutically acceptable salt of substituted quinazoline compound”

(INT: CL, C07D 239/72)


139448

This invention provides pharmaceutically acceptable salt of a compound of formula 1 having the structure



wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminomethyl, N-alkylaminomethyl of 2-7 carbon atoms, N,N-dialkylaminomethyl of 3-7 carbon atoms, mercapto, methylmercapto, and benzoylamino;



R<sub>5</sub> is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,

R<sub>7</sub>-(C(R<sub>6</sub>)<sub>2</sub>)<sub>s</sub>-      R<sub>7</sub>(C(R<sub>6</sub>)<sub>2</sub>)<sub>p</sub>-M—(C(R<sub>6</sub>)<sub>2</sub>)<sub>r</sub>-

R<sub>8</sub>R<sub>9</sub>-CH-M—(C(R<sub>6</sub>)<sub>2</sub>)<sub>r</sub>- or Het-W-(C(R<sub>6</sub>)<sub>2</sub>)<sub>r</sub>-

R<sub>8</sub>, and R<sub>9</sub> are each, independently, -

(C(R<sub>6</sub>)<sub>2</sub>)<sub>r</sub>NR<sub>6</sub>R<sub>6</sub>, or -(C(R<sub>6</sub>)<sub>2</sub>)<sub>r</sub>OR<sub>6</sub>;

J is independently hydrogen, chlorine, fluorine, or bromine; Q is alkyl of 1-6 carbon atoms or hydrogen;

a = 0 or 1;

g = 1-6;

k = 0-4;

n is 0-1;

p = 2-4;

q = 0-4;

r = 1-4;

s = 1-6;


u = 0-4 and v = 0-4, wherein the sum of u+v is 2-4;

provided that when:

Z is NH;

n is O;

R<sub>2</sub> is selected from the group consisting of



R<sub>5</sub> is independently and exclusively hydrogen, alkyl


of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms;

R1 is hydrogen, halogen, alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms;

R4 is hydrogen, halogen, alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms; and

R3 is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, or trifluoromethyl;

X is not a phenyl ring exclusively substituted with one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, amino, and alkanoylamino of 1-6 carbon atoms; Further provided that when R2 is



and R5 is hydrogen or alkyl of 1-6 carbon atoms, R3 is not halogen and still further provide that when R6 is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety bond to a nitrogen or oxygen atom through a saturated carbon atom: and finally provided that when Y is -NR6-or R7 is -NR6R6 then g = 2-6; when M is -O- and R7 is -OR6 then p = 1-4; when Y is -NR6-then K = 2-4; when Y is -O- and M or W is -O-then K=1-4 and when W is a bond with Het bonded through a nitrogen atom and Y is -O-or-NR6- then K= 2-4: which are useful as antineoplastic agents and in the treatment of certain kidney diseases, such as polycystic kidney disease.







1009/2006 Wyeth  
USA.

“Apharmaceutically acceptable salt of thieno[3,2-  
b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-  
5-carbonitrile”

(C07D 519/00)

139449

This invention provides pharmaceutical acceptable  
salt of compound of formula (1a) – (1f)



Wherein;

X, R(1), and R(2), are defined hereinbefore in the  
specification, which are useful in the treatment of  
cancer, stroke, osteoporosis, polycystic kidney  
disease, autoimmune disease, rheumatoid arthritis  
and transplant rejection


1185/2007 Pfizer Products Inc.  
USA.

“1-Benzyl-6-methoxy-3,4-dihydro-1H-naphthalen-2-  
one”

(A61K 13/00)

139450

The present invention provides intermediate  
compound of formula (VIII)




1186/2007 Pfizer Products Inc. USA. "Pharmaceutical salt of 1-Benzyl-6-methoxy-3,4-dihydro-1H-naphthalen-2-one"

(A61K 13/00)

139451

The present invention provides non-steroidal pharmaceutical acceptable salt of the compound of formula I which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical composition containing these compound. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediate and process for preparing these compound.



XXXXXXXXXXXX

(Mrs. Yasmeen Abbasi)  
 Controller of Patents  
 Ph: 9215488